This prospective study will examine eosinophils in various biological materials to compare the detection in those materials and ascertain the prognostic and predictive role of eosinophils in untreated non-small cell lung cancer patient.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
200
After premedication with 400 μg inhaled salbutamol, sputum will be induced by inhalation of hypertonic (NaCl 3%) or isotonic (NaCl 0.9%) saline combined according to the FEV-1 value (\> or ≤ than 65% predicted). Saline will be combined with additional salbutamol delivered by an ultrasonic nebulizer (Ultra-Neb 2000; Devilbiss, Somerset, PA, USA) with an output set at 0.9 ml/min. Each subject will inhale the aerosol for three consecutive periods of 5 min for a total of 15 min. For safety reasons, FEV-1 will be monitored throughout the induction and will be stopped if FEV-1 would fall by more than 20% from baseline.
As per standard practice, biopsies will be taken from the primary tumour site or from a metastatic site.
CHU de Liège
Liège, Belgium
RECRUITINGDetection of eosinophils in untreated non-small cell lung cancer patients
Concentration of eosinophils will be used in various bodily materials as described above.
Time frame: Baseline (pre-treatment)
Prognostic and predictive value of eosinophils in non-small cell lung cancer patients
Time frame: Baseline (pre-treatment) and, if immunotherapy, after 3 months of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
When available, the remaining material from a patient's bronchoalveolar lavage will be collected.
As per standard practice, blood will be drawn from patients before and during treatment. Data on white blood cells will be collected.